|
Year
|
Title
|
Authors
|
Publication
|
|
2022
|
Trends in allogeneic hematopoietic cell transplantation utilization and estimated unmet need among Medicare beneficiaries with acute myeloid leukemia
|
Mau L-W, Preussler JM, Meyer C, Senneka M, Steinert P, Khera N, Saber W
|
Transplant Cell Ther
|
|
2022
|
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
|
Furqan F, Ahn KW, Chen Y, Kaur M, Abutalib SA, Ahmed N, Ahmed S, Kharfan-Dabaja MA, Friedberg J, Gregory T, Hill L, Sterling C, Barta SK, Shadman M, Perales M-A, Zain J, Herrera AF, Sauter C, Hamadani M
|
Br J Haematol
|
|
2022
|
Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis.
|
Brown DW, Zhou W, Wang Y, Jones K, Luo W, Dagnall C, Teshome K, Klein A, Zhang T, Lin SH, Lee OW, Khan S, Vo JB, Hutchinson A, Liu J, Wang J, Zhu B, Hicks B, Martin AS, Spellman SR, Wang T, Deeg HJ, Gupta V, Lee SJ, Freedman ND, Yeager M, Chanock SJ, Savage SA, Saber W, Gadalla SM, Machiela MJ
|
Nat Commun 13(1):5284
|
|
2022
|
Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States.
|
Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, Lin Y, Perales MA, Lunning MA, Herr MM, Hill BT, Ganguly S, Dong H, Nikiforow S, Hooper M, Kawashima J, Xu H, Pasquini MC
|
Transplant Cell Ther 28(9):581.e1-581.e8
|
|
2022
|
A new strategy for systematically classifying HLA alleles into serological specificities.
|
Osoegawa K, Marsh SGE, Holdsworth R, Heidt S, Fischer G, Murphey C, Maiers M, Fernández Viňa MA
|
HLA 100(3):193-231
|
|
2022
|
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): A multicentre, single-arm, phase 2 trial.
|
DeZern AE, Eapen M, Wu J, Talano JA, Solh M, Dávila Saldaña BJ, Karanes C, Horwitz ME, Mallhi K, Arai S, Farhadfar N, Hexner E, Westervelt P, Antin JH, Deeg HJ, Leifer E, Logan BR, Horowitz MM, Jones RJ, Pulsipher MA
|
Lancet Haematol 9(9):e660-e669
|
|
2022
|
The impact of pre-apheresis Health Related Quality of Life on peripheral blood progenitor cell yield and donor’s health and outcome: Secondary analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials.
|
Farhadfar N, Ahn KW, Bo-Subait S, Logan B, Stefanski HE, Hsu JW, Panch S, Confer D, Liu H, Badawy SM, Beitinjaneh A, Diaz MA, Hildebrandt GC, Kelkar AH, Lazarus HM, Murthy HS, Preussler JM, Schears RM, Sharma A, Poel M, Bruce JG, Pulsipher MA, Shaw BE, Wingard JR, Switzer GE
|
Transplant Cell Ther 28(9):603.e1-603.e7
|
|
2022
|
Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes.
|
McReynolds LJ, Rafati M, Wang Y, Ballew BJ, Kim J, Williams VV, Zhou W, Hendricks RM, Dagnall C, Freedman ND, Carter B, Strollo S, Hicks B, Zhu B, Jones K, Paczesny S, Marsh SGE, Spellman SR, He M, Wang T, Lee SJ, Savage SA, Gadalla SM
|
Blood 140(8):909-921
|
|
2022
|
Germline predisposition variants occur in myelodysplastic syndrome patients of all ages.
|
Feurstein SK, Trottier AM, Estrada-Merly N, Pozsgai MJ, McNeely KE, Drazer MW, Ruhle B, Sadera K, Koppayi AL, Scott BL, Oran B, Nishihori T, Agrawal V, Saad A, Lindsley RC, Nakamura R, Kim S, Hu ZH, Sobecks RM, Spellman SR, Saber W, Godley LA
|
Blood
|
|
2022
|
A core group of structurally similar HLA-DPB1 alleles drives permissiveness after hematopoietic cell transplantation.
|
Arrieta-Bolaños E, Crivello P, He M, Wang T, Gadalla SM, Paczesny S, Marsh SGE, Lee SJ, Spellman SR, Bolon YT, Fleischhauer K
|
Blood 140(6):659-663
|
|
2022
|
Natural killer cell alloreactivity predicted by killer cell immunoglobulin-like receptor ligand mismatch does not impact engraftment in umbilical cord blood and haploidentical stem cell transplantation.
|
Otegbeye F, Vina MAF, Wang T, Bolon YT, Lazaryan A, Beitinjaneh A, Bhatt VR, Castillo P, Marsh SGE, Hildebrandt GC, Assal A, Brown VI, Hsu J, Spellman S, de Lima M, Lee SJ
|
Transplant Cell Ther 28(8):483.e1-483.e7
|
|
2022
|
Outcomes of autologous hematopoietic cell transplantation in older patients with diffuse large B-cell lymphoma.
|
Munshi PN, Chen Y, Ahn KW, Awan FT, Cashen A, Shouse G, Shadman M, Shaughnessy P, Zurko J, Locke FL, Goodman AM, Bisneto JCV, Sauter C, Kharfan-Dabaja MA, Meyers G, Jaglowski S, Herrera A, Hamadani M
|
Transplant Cell Ther 28(8):487.e1-487.e7
|
|
2022
|
Suitability of haematopoietic cell donors: Updated consensus recommendations from the WBMT standing committee on donor issues.
|
Worel N, Aljurf M, Anthias C, Buser AS, Cody M, Fechter M, Galeano S, Greinix HT, Kisch AM, Koh MBC, Mengling T, Nicoloso G, Niederwieser D, Pulsipher MA, Seber A, Shaw BE, Stefanski HE, Switzer GE, Szer J, van Walraven SM, Yang H, Halter JP
|
Lancet Haematol 9(8):e605-e614
|
|
2022
|
Proceedings from the BMT CTN Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma
|
Holstein SA, Bhutani M, Hillengass J, Pasquini M, Shah N, Usmani SZ, McCarthy P
|
Transplant Cell Ther 28(8):446-454
|
|
2022
|
Are we making PROGRESS in preventing graft-versus-host disease and improving clinical outcomes? Impact of BMT CTN 1301 study results on clinical practice.
|
Hamilton BK, Cutler C, Divine C, Juckett M, LeMaistre C, Stewart S, Wilder J, Horowitz M, Khera N, Burns LJ
|
Transplant Cell Ther 28(8):419-425
|
|
2022
|
Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis.
|
Dholaria B, Radujkovic A, Estrada-Merly N, Sirait T, Kim S, Hernández-Boluda JC, Czerw T, Hayden PJ, Kansagra A, Ho VT, Nishihori T, Shaughnessy P, Scott B, Nakamura R, Oran B, Kharfan-Dabaja M, Savani BN, McLornan D, Yakoub-Agha I, Saber W
|
Br J Haematol 198(4):785-789
|
|
2022
|
HLA-matching with PTCy: A reanalysis of a CIBMTR dataset with propensity score matching and donor age.
|
Ambinder A, Jain T, Tsai HL, Horowitz MM, Jones RJ, Varadhan R
|
Blood Adv 6(14):4335-4346
|
|
2022
|
Health Related Quality of Life in Young Adults Survivors of Hematopoietic Cell Transplantation
|
Rotz SJ, Yi JC, Hamilton BK, Preussler JM, Cerny J, Deol A, Jim H, Khera N, Hahn T, Hashmi S, Holtan S, Jaglowski SM, Loren AW, McGuirk J, Reynolds J, Saber W, Savani BN, Stiff P, Uberti J, Wingard JR, Wood WA, Baker KS, Majhail NS, Syrjala KL
|
Transplant Cell Ther
|
|
2022
|
Association of chronic graft-versus-host disease with late effects following allogeneic hematopoietic cell transplantation for children with hematologic malignancy.
|
Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Auletta JJ, Badawy SM, Bhatt N, Bhatt VR, Cahn JY, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla S, Gale RP, Hashem H, Hashmi S, Hematti P, Hong S, Hossain NM, Inamoto Y, Lekakis LJ, Modi D, Patel S, Sharma A, Solomon S, Couriel DR
|
Transplant Cell Ther
|
|
2022
|
Characteristics of graft-versus-host disease (GvHD) after post-transplant cyclophosphamide versus conventional GvHD prophylaxis.
|
Saliba RM, Majid AA, Pidala J, Arora M, Spellman SR, Hemmer MT, Wang T, Abboud C, Ahmed S, Antin JH, Beitinjaneh A, Buchbinder D, Byrne M, Cahn JY, Choe H, Hanna R, Hematti P, Kamble RT, Kitko CL, Laughlin M, Lekakis L, MacMillan ML, Martino R, Mehta PA, Nishihori T, Patel SS, Perales MA, Rangarajan HG, Ringdén O, Rosenthal J, Savani BN, Schultz KR, Seo S, Teshima T, van der Poel M, Verdonck LF, Weisdorf D, Wirk B, Yared JA, Schriber J, Champlin R, Ciurea S
|
Transplant Cell Ther
|
|
2022
|
Triplet therapy, transplantation, and maintenance until progression in myeloma.
|
Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD jr, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble R, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralt SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Naddeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson K, Munshi NC
|
N Engl J Med 387(2):132-147
|
|
2022
|
Multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: Results of the BMT CTN 1302 Trial
|
Bashir Q, Nishihori T, Pasquini MC, Martens MJ, Wu J, Alsina M, Anasetti C, Brunstein CG, Dawson P, Efebera Y, Gasparetto C, Geller N, Giralt S, Hall AC, Koreth J, McCarthy P, Scott E, Stadtmauer E, Vesole D, Hari P
|
Transplant Cell Ther
|
|
2022
|
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.
|
Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansend DK, Anderson LD, Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee C, Mian H, Nathan S, Savani B, Kumar S, Qazilbash M, Shah N, D'Souza A
|
Blood Adv 6(13):3991-3995
|
|
2022
|
Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to compare long-term outcomes after hematopoietic cell transplantation to those in siblings without sickle cell disease and in nontransplanted individuals with sickle cell disease: Design and feasibility study.
|
Krishnamurti L, Arnold SD, Haight A, Abraham A, Guilcher GM, John T, Bakshi N, Shenoy S, Syrjala K, Martin PL, Chaudhury S, Eames G, Olowoselu OF, Hsieh M, De La Fuente J, Kasow KA, Stenger E, Mertens A, El-Rassi F, Lane P, Shaw BE, Meacham L, Archer D
|
JMIR Res Protoc 11(7):e36780
|
|
2022
|
Male-specific late effects in adult hematopoietic cell transplantation recipients: A systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.
|
Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, Badawy SM, Burns L, Eissa H, Murthy HS, Prasad P, Sharma A, Suelzer E, Agrawal V, Aljurf M, Baker K, Basak GW, Buchbinder D, DeFilipp Z, Grkovic LD, Dias A, Einsele H, Eisenberg ML, Epperla N, Farhadfar N, Flatau A, Gale RP, Greinix H, Hamilton BK, Hashmi S, Hematti P, Jamani K, Maharaj D, Murray J, Naik S, Nathan S, Pavletic S, Peric Z, Pulanic D, Ross R, Salonia A, Sanchez-Ortega I, Savani BN, Schechter T, Shah AJ, Smith SM, Snowden JA, Steinberg A, Tremblay D, Vij SC, Walker L, Wolff D, Yared JA, Schoemans H, Tichelli A
|
Bone Marrow Transplant 57(7):150-1163
|
|
2022
|
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.
|
Stewart MD, McCall B, Pasquini M, Yang AS, Britten CD, Chuk M, De Claro RA, George B, Gormley N, Horowitz MM, Kowack E, McCoy C, Morrow PK, Okoye E, Ricafort R, Rossi J, Sharon E, Theoret M, Vegni F, Yu T, Allen J
|
Cytotherapy 24(7):742-749
|
|
2022
|
Race and survival in unrelated hematopoietic cell transplantation.
|
Morishima Y, Morishima S, Stevenson P, Kodera Y, Horowitz M, McKallor C, Malkki M, Spellman SR, Gooley T, Petersdorf EW
|
Transplant Cell Ther 28(7):357.e1-357.e6
|
|
2022
|
Impact of center experience with donor type on outcomes: A secondary analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for accrual June 2012Open for Accrual June 2012.
|
Brunstein CG, O'Donnell PV, Logan B, Dawson P, Costa L, Cutler C, Craig M, Hogan W, Horowitz MM, Horwitz ME, Karanes C, Magenau JM, Malone A, McCarty J, McGuirk JP, Morris LE, Rezvani AR, Salit R, Vasu S, Eapen M, Fuchs EJ
|
Transplant Cell Ther 28(406):e1-406.e6
|
|
2022
|
Updated trends in hematopoietic cell transplantation in the United States with an additional focus on adolescent and young adult transplantation activity and outcomes.
|
Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, Burns LJ, Chhabra S, Christianson D, Cusatis R, Devine SM, D'Souza A, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini M, Pérez WS, Riches M, Rizzo D, Saber W, Spellman SR, Stefanski HE, Steinert P, Weisdorf D, Horowitz M, Auletta JJ, Shaw BE, Arora M
|
Transplant Cell Ther 409:e1-409.e10
|
|
2022
|
Age is no barrier for adults undergoing HCT for AML in CR1: Contemporary CIBMTR analysis.
|
Maakaron JE, Zhang M-J, Chen K, Abhyankar S, Bhatt VR, Chhabra S, El Jurdi N, Farag SS, He F, Juckett M, de Lima M, Majhail N, van der Poel M, Saad A, Savani B, Ustun C, Waller EK, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D
|
Bone Marrow Transplant 57(6):911-917
|
|
2022
|
Male-Specific late effects in adult hematopoietic cell transplantation recipients: A systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.
|
Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, Badawy SM, Burns L, Eissa H, Murthy HS, Prasad P, Sharma A, Suelzer E, Agrawal V, Aljurf M, Baker K, Basak GW, Buchbinder D, DeFilipp Z, Grkovic LD, Dias A, Einsele H, Eisenberg ML, Epperla N, Farhadfar N, Flatau A, Gale RP, Greinix H, Hamilton BK, Hashmi S, Hematti P, Jamani K, Maharaj D, Murray J, Naik S, Nathan S, Pavletic S, Peric Z, Pulanic D, Ross R, Salonia A, Sanchez-Ortega I, Savani BN, Schechter T, Shah AJ, Smith SM, Snowden JA, Steinberg A, Tremblay D, Vij SC, Walker L, Wolff D, Yared JA, Schoemans H, Tichelli A
|
Transplant Cell Ther 28(6):335.e1-335.e17
|
|
2022
|
Noninfectious pulmonary toxicity after allogeneic hematopoietic cell transplantation.
|
Patel SS, Ahn KW, Khanal M, Bupp C, Allbee-Johnson M, Majhail NS, Hamilton BK, Rotz SJ, Hashem H, Beitinjaneh A, Lazarus HM, Krem MM, Prestidge T, Bhatt NS, Sharma A, Gadalla SM, Murthy HS, Broglie L, Nishihori T, Freytes CO, Hildebrandt GC, Gergis U, Seo S, Wirk B, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S
|
Transplant Cell Ther 28(6):310-320
|
|
2022
|
Long-term survival after hematopoietic cell transplant for sickle cell disease compared to the United States population.
|
St Martin A, Hebert KM, Serret-Larmande A, Jouhet V, Hughes E, Stedman J, DeSain T, Pillion D, Lyons JC, Steinert P, Avillach P, Eapen M
|
Transplant Cell Ther 28(6):325.e1-325.e7
|
|
2022
|
Telomere length and epigenetic clocks as markers of cellular aging: A comparative study.
|
Pearce EE, Alsaggaf R, Katta S, Dagnall C, Aubert G, Hicks BD, Spellman SR, Savage SA, Horvath S, Gadalla SM
|
GeroScience 44(3):1861-1869
|
|
2022
|
Increasing access to hematopoietic cell transplantation in Latin America: Results of the 2018 LABMT activity survey and trends since 2012.
|
Correa C, Gonzalez-Ramella O, Baldomero H, Basquiera AL, Baena R, Arcuri L, Puga B, Rosales C, Chávez M, Hernández C, Maldonado B, Gómez-De León A, Mendoza N, Frutos C, Aranda L, Díaz L, Hernández M, Seber A, Karduss A, Jaimovich G, Martínez-Rolon J, Bonfim C, Greinix H, Koh MBC, Aljurf M, Iida M, Saber W, Niederwieser D, Atsuta Y, Galeano S
|
Bone Marrow Transplant 57(6):881-888
|
|
2022
|
HLA-DQ heterodimers in hematopoietic cell transplantation.
|
Petersdorf EW, Bengtsson M, Horowitz MM, McKallor C, Spellman SR, Spierings E, Gooley TA, Stevenson PA
|
Blood 139(20):3009-3017
|
|
2022
|
Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians.
|
Broglie L, Friend BD, Chhabra S, Bupp C, Schiller GJ, Logan B, Pasquini MC, Savani B, Stadtmauer EA, Thakar MS, Sorror M
|
Leuk Lymphoma
|
|
2022
|
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma
|
D'Souza A, Brazauskas R, Stadtmauer E, Pasquini M, Hari P, Bashey A, Callander N, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz M, Koreth J, Landau H, Brunstein CG, McCarthy P, Qazilbash M, Giralt S, Krishnan A, Flynn K
|
Am J Hematol
|
|
2022
|
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.
|
Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gormley N, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Kwong YL, Little RF, Matasar MJ, Mateos M-V, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Nair A, Nastoupil L, Robertson K, Sidana S, Smedby KE, Sonneveld P, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Seymour JF, Habermann TM
|
Lancet Haematol 9(5):e374-e384
|
|
2022
|
Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?
|
Abou-Ismail MY, Fraser R, Allbee-Johnson M, Metheny L 3rd, Ravi G, Ahn KW, Bhatt NS, Lazarus HM, de Lima M, El Jurdy N, Hematti P, Beitinjaneh AM, Nishihori T, Badawy SM, Sharma A, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S
|
Br J Haematol 197(3):326-338
|
|
2022
|
One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors.
|
Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, Elhaddad A, Frutos C, Galeano S, Hamad N, Hamidieh AA, Hashmi S, Ho A, Horowitz MM, Iida M, Jaimovich G, Karduss A, Kodera Y, Kröger N, Péffault de Latour R, Lee JW, Martínez-Rolón J, Pasquini MC, Passweg J, Paulson K, Seber A, Snowden JA, Srivastava A, Szer J, Weisdorf D, Worel N, Koh MBC, Aljurf M, Greinix H, Atsuta Y, Saber W
|
Haematologica 107(5):1045
|
|
2022
|
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia.
|
Baccarani M, Bonifazi F, Soverini S, Castagnetti F, Gugliotta G, Saber W, Estrada-Merly N, Rosti G, Gale RP
|
Leukemia 36(5):1227-1236
|
|
2022
|
Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.
|
Jimenez Jimenez AM, De Lima M, Komanduri KV, Wang TP, Zhang M-J, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn J-Y, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez MAD, Elsawy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Khera N, Krem MM, Lazaryan A, Maakaron J, Martino R, McGuirk J, Michelis FV, Milone G, Mishra A, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Patel S, Saad A, Seo S, Sharma A, Solh M, Verdonck LF, Wirk B, Yared JA, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D
|
Bone Marrow Transplant 57(5):852
|
|
2022
|
Impact of human T cell lymphotropic virus type 1 and 2 infection on survival following stem cell transplantation.
|
Gupta VK, El-Jawahri A, Orkev G, Johnson MH, Weinberg J, Goodrich C, Janakiram M, Sloan JM
|
Transplant Cell Ther 28(5):276.e1-276.e5
|
|
2022
|
Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: Evidence of durable benefit.
|
Mei M, Hamadani M, Ahn KW, Chen Y, Kharfan-Dabaja MA, Sauter C, Herrera AF
|
Haematologica 107(5):1214-1217
|
|
2022
|
Genetic associations with immune-mediated outcomes after allogeneic hematopoietic cell transplantation.
|
Martin PJ, Levine DM, Storer BE, Sather CL, Spellman SR, Hansen JA
|
Blood Adv 6(8):2608-2617
|
|
2022
|
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis.
|
Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, Meng Z, Bilal Abid M, Aljurf M, Bacher VU, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Copelan E, Cutler C, DeFilipp Z, Diaz Perez MA, Farhadfar N, Freytes C, Gadalla S, Ganguly S, Gale RP, Gergis U, Grunwald M, Hamilton B, Hashmi S, Hildebrandt G, Lazarus H, Litzow M, Munker R, Murthy H, Nathan S, Nishihori T, Rizzieri D, Seo S, Shah M, Solh M, Verdonck L, Vij R, Sobecks R, Oran B, Scott B, Saber W, Nakamura R
|
Haematologica
|
|
2022
|
HLA homozygosity and likelihood of sensitization in kidney transplant candidates.
|
Rushakoff JA, Gragert L, Pando MJ, Stewart D, Huang E, Kim I, Jordan S, Lindblad K, Zhang X, Lalli P, Patel JK, Kobashigawa JA, Kransdorf EP
|
Transplant Direct 8(5):e1312
|
|
2022
|
Outcomes of allogeneic hematopoietic cell transplantation in T cell prolymphocytic leukemia: A contemporary analysis from the Center for International Blood and Marrow Transplant Research.
|
Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W
|
Transplant Cell Ther 28(4):187.e1-187.e10
|
|
2022
|
Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.
|
Savani M, Ahn KW, Chen Y, Ahmed S, Cashen AF, Shadman M, Modi D, Khimani F, Cutler CS, Zain J, Brammer JE, Rezvani AR, Fenske TS, Sauter CS, Kharfan-Dabaja MA, Herrera AF, Hamadani M
|
Br J Haematol 197(2):212-222
|
|
2022
|
Correction to: A SAS macro for estimating direct adjusted survival functions for time-to-event data with or without left truncation.
|
Hu Z-H, Wang H-L, Gale RP, Zhang M-J
|
Bone Marrow Transplant 57(4):693
|
|
2022
|
A calibrated Bayesian method for the stratified proportional hazards model with missing covariates.
|
Kim S, Kim J-K, Ahn KW
|
Lifetime Data Anal 28(2):169-193
|
|
2022
|
Competing risks regression models with covariates-adjusted censoring weight under the generalized case-cohort design.
|
Xu Y, Kim S, Zhang M-J, Couper D, Ahn KW
|
Lifetime Data Anal 28(2):241-262
|
|
2022
|
Two-sample survival probability curves: A graphical approach for the analysis of time to event data in clinical trials.
|
Castro-Pearson S, Le CT, Luo X
|
Contemp Clin Trials 115:106707
|
|
2022
|
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide.
|
Fuchs EJ, McCurdy SR, Solomon SR, Wang T, Herr MR, Modi D, Grunwald MR, Nishihori T, Kuxhausen M, Fingerson S, McKallor C, Bashey A, Kasamon YL, Bolon Y-T, Saad A, McGuirk J, Paczesny S, Gadalla SM, Marsh SGE, Shaw BE, Spellman SR, Lee SJ, Petersdorf EW
|
Blood 139(10):1452-1468
|
|
2022
|
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
|
Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi PN, Beitinjaneh A, Reagan P, Herrera AF, Sauter CS, Kharfan-Dabaja MA, Hamadani M
|
Blood 139(9):1330-1339
|
|
2022
|
Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors.
|
Guru Murthy GS, Kim S, Hu Z-H, Estrada-Merly N, Abid MB, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bredeson C, Cahn J-Y, Cerny J, Diaz Perez MA, Farhadfar N, Gale RP, Ganguly S, Gergis U, Hildebrandt GC, Grunwald MR, Hashmi S, Hossain NM, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Hamilton BK, Lazarus HM, Liesveld J, Litzow M, Marks DI, Murthy HS, Nathan S, Nazha A, Nishihori T, Patel SS, Pawarode A, Rizzieri D, Savani B, Seo S, Solh M, Ustun C, van der Poel M, Verdonck LF, Vij R, Wirk B, Oran B, Nakamura R, Scott B, Saber W
|
JAMA Oncol 8(3):404-411
|
|
2022
|
Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders.
|
Marsh RA, Hebert K, Kim S, Dvorak CC, Aquino VM, Baker KS, Chellapandian D, Dávila Saldaña B, Duncan CN, Eckrich MJ, Georges GE, Olson TS, Pulsipher MA, Shenoy S, Stenger E, Lugt MV, Yu LC, Gennery AR, Eapen M
|
J Allergy Clin Immunol 149(3):1097-1104.e2
|
|
2022
|
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).
|
Dispenzieri A, Krishnan A, Arendt B, Blackwell B, Wallace PK, Dasari S, Vogl DT, Efebera Y, Fei M, Geller N, Giralt S, Hahn T, Howard A, Kohlhagen M, Landau H, Hari P, Pasquini MC, Qazilbash MH, McCarthy P, Shah N, Vesole D, Stadtmauer E, Murray D
|
Blood Cancer J 12(2):27
|
|
2022
|
Outcome of allogeneic transplantation for mature T-cell lymphomas: Impact of donor source and disease characteristics.
|
Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, Chen Y, Boumendil A, Zain J, Castagna L, Cashen AF, Blaise D, Shadman M, Pastano R, Khimani F, Arat M, Dietrich S, Schmitz N, Glass B, Kharfan-Dabaja MA, Corradini P, Sauter CS, Montoto S, Kwon M, Herrera AF, Dreger P
|
Blood Adv 6(3):920-930
|
|
2022
|
Impact of induction therapy with VRD versus VCD on outcomes in patients with multiple myeloma in partial response or better undergoing upfront autologous stem cell transplantation.
|
Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD Jr, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A
|
Transplant Cell Ther 8(2):e1-83.e9
|
|
2022
|
Outcomes in hematopoietic stem cell transplantation for congenital amegakaryocytic thrombocytopenia.
|
Cancio M, Hebert K, Kim S, Aljurf M, Olson T, Anderson E, Burroughs L, Vatsayan A, Myers K, Hashem H, Hanna R, Horn B, Prestidge T, Boelens JJ, Boulad F, Eapen M
|
Transplant Cell Ther 28(2):101.e1-101.e6
|
|
2022
|
Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD.
|
Meyers G, Hamadani M, Martens M, Ali H, Choe H, Dawson P, Harris AC, van Hooren E, Klaassen W, Leifer E, MacMillan ML, van Oosterhout Y, Perez L, Pusic I, Vo P, Levine JE
|
Bone Marrow Transplant 57(2):302-303
|
|
2022
|
A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients.
|
Tan CR, Estrada-Merly N, Landau H, Lekakis L, Banerjee R, Mian H, Usmani SZ, Hanbali A, Lazarus HM, Kyle RA, Dholaria B, Bal S, Strouse C, Murthy HS, Wirk B, Nishihori T, Kumar S, Shah N, Qazilbash M, D'Souza A
|
Bone Marrow Transplant 57(2):295-298
|
|
2022
|
Umbilical cord blood or HLA-haploidentical transplantation: Real-world outcomes versus randomized trial outcomes.
|
O'Donnell PV, Brunstein CG, Fuchs EJ, Zhang M-J, Allbee-Johnson M, Antin JH, Leifer ES, Elmariah H, Grunwald MR, Hashmi H, Horowitz MM, Magenau JM, Majhail N, Milano F, Morris LE, Rezvani AR, McGuirk JP, Jones RJ, Eapen M
|
Transplant Cell Ther 28(2):109.e1-109.e8
|
|
2022
|
Adding centralized electronic patient-reported outcome data collection to an established international clinical outcomes registry.
|
Cusatis R, Flynn KE, Vasu S, Pidala J, Muffly L, Uberti J, Tamari R, Mattila D, Mussetter A, Bruzauskas R, Chen M, Leckrone E, Myers J, Mau L-W, Rizzo JD, Saber W, Horowitz M, Lee SJ, Burns LJ, Shaw B
|
Transplant Cell Ther 28(2):112.e1-112.e9
|
|
2022
|
Assessment of genomic prediction reliability and optimization of experimental designs in multi-environment trials.
|
Rio S, Akdemir D, Carvalho T, Sánchez JIY
|
Theor Appl Genet 135(2):406-419
|
|
2022
|
Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies.
|
Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA
|
J Clin Oncol 40(4):356-368
|
|
2022
|
Number of HLA-mismatched eplets is not associated with major outcomes in haploidentical transplantation with post-transplantation cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study.
|
Zou J, Wang T, He M, Bolon YT, Gadalla SM, Marsh SGE, Kuxhausen M, Gale RP, Sharma A, Assal A, Prestidge T, Aljurf M, Cerny J, Paczesny S, Spellman SR, Lee SJ, Ciurea SO
|
Transplant Cell Ther 28(2):107.e1-107.e8
|
|
2022
|
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: A noncomparative cohort analysis.
|
Hamadani M, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, Lazaryan A, Bhatt VR, Daly A, Lulla P, Ciurea S, Gauthier J, Agrawal V, Grover NS, Lekakis L, Modi D, Dahi PB, Herr MM, Johnson PC, Hashmi H, Hematti P, Locke FL
|
Blood Adv 6(2):486-494
|
|
2022
|
Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.
|
Wieduwilt MJ, Metheny L, Zhang MJ, Wang H-L, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao NJ, Rizzieri D, Gale RP, Gadalla SM, Cairo MS, Mussetti A, Gore SD, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson CN, Diaz Perez MA, Cassaday R, Savani BN, Ballen KK, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel M, van der Poel MWM, Grunwald MR, Liesveld JL, Kamble RT, McGuirk JP, Munker R, Cahn J-Y, Lee JW, Freytes CO, Krem M, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringden O, Friend BD, Cerny J, Choe HK, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, De Lima M, Litzow MR, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W
|
Blood Adv 6(1):339-357
|
|
2022
|
Assessment of HLA-B genetic variation with an HLA-B leader tool and implications in clinical transplantation.
|
Sajulga R, Bolon Y-T, Maiers MJ, Petersdorf EW
|
Blood Adv 6(1):270-280
|
|
2022
|
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.
|
Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang M-J, Bo-Subait K, Sanchez J, Wang H-L, Aljurf M, Assal A, Bacher VU, Badawy SM, Bejanyan N, Bhatt VR, Bredeson CN, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus H, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson R, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan C, Sandmaier B, Litzow M, Kebriaei P, Weisdorf D, Zhang Y, Tallman MS, Saber W
|
Blood Adv 6(3):828-847
|
|
2022
|
Decrease post-transplant relapse using donor-derived expanded NK-cells.
|
Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani A, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE
|
Leukemia 36(1):155-164
|
|
2022
|
Chronic graft-versus-host disease, nonrelapse mortality, and disease relapse in older versus younger adults undergoing matched allogeneic peripheral blood hematopoietic cell transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
|
Bhatt VR, Wang T, Chen K, Kitko CL, MacMillan ML, Pidala JA, Malki MM, Badawy SM, Beitinjaneh A, Ganguly S, Hamilton B, Hildebrandt GC, Lekakis LJ, Liu H, Maziarz RT, Modi D, Murthy HS, Preussler JM, Sharma A, Spellman SR, Arora M, Lee SJ
|
Transplant Cell Ther 28(1):34-42
|
|
2022
|
Case-cohort design in hematopoietic cell transplant studies.
|
Cai J, Kim S
|
Bone Marrow Transplant 57(1):1-5
|
|
2022
|
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis.
|
Pasvolsky O, Yeshurun M, Fraser R, Estrada-Merly N, Rozovski U, Shargian-Alon L, Assal A, Banerjee R, Bumma N, Gale RP, Hagen P, Holmberg L, Hossain NM, Lazarus HM, Lee C, Mian H, Miller KC, Nathan S, Nagler A, Nishihori T, Parrondo RD, Patel S, Schroeder MA, Usmani SZ, Wang T, Wirk B, Kumar S, Shah N, Qazilbash MH, D'Souza A
|
Bone Marrow Transplant 57(1):31-37
|
|
2022
|
Post-transplantation cyclophosphamide is associated with an increase in non-cytomegalovirus herpesvirus infections in patients with acute leukemia and myelodysplastic syndrome.
|
Singh A, Dandoy CE, Chen M, Kim S, Mulroney CM, Kharfan-Dabaja MA, Ganguly S, Maziarz RT, Kanakry CG, Kanakry JA, Patel SS, Hill JA, De Oliveir S, Taplitz R, Hematti P, Lazarus HM, Abid MB, Goldsmith SR, Romee R, Komanduri KV, Badawy SM, Friend BD, Beitinjaneh A, Politikos I, Perales M-A, Riches M
|
Transplant Cell Ther 2(1):48.e1-48.e10
|
|
2022
|
New indications and platforms for CAR-T therapy in lymphomas beyond DLBCL.
|
Iqbal M, Savani BN, Hamadani M
|
EJHaem 3(Suppl 1):11-23
|
|
2022
|
A SAS macro for estimating direct adjusted survival functions for time-to-event data with or without left truncation.
|
Hu Z-H, Wang H-L, Gale RP, Zhang M-J
|
Bone Marrow Transplant 57(1):6-10
|
